Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | THRB | P10828 | 1/20 | 0.74 |
| ▸ | CA9 | Q16790 | 5/20 | 0.50 |
| ▸ | CA12 | O43570 | 4/20 | 0.50 |
| ▸ | CA1 | P00915 | 4/20 | 0.50 |
| ▸ | CA2 | P00918 | 4/20 | 0.50 |
| ▸ | CA7 | P43166 | 4/20 | 0.50 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.50 |
| ▸ | MAOB | P27338 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.41 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.41 |
| ▸ | TAS1R2 | Q8TE23 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | PRKCI | P41743 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3712557 | 1.00 | THRB (0.74) | THRBCA9CA12CA1CA2 | |
| SCHEMBL11846322 | 0.88 | THRB (0.54) | THRBCA9CA12CA1CA2 | |
| SCHEMBL105807 | 0.85 | THRB (1.00) | THRBCA9CA12CA1CA2 | |
| SCHEMBL4147953 | 0.82 | CA12 (0.70) | THRBCA9CA12CA1CA2 | |
| SCHEMBL24753974 | 0.81 | THRB (0.53) | THRBCA9CA12CA1CA2 | |
| SCHEMBL31347964 | 0.80 | MAOB (0.54) | THRBCA9CA12CA1CA2 | |
| SCHEMBL5724714 | 0.80 | THRB (0.46) | THRBMAOBKMT2AHPGDALDH1A1 | |
| SCHEMBL28607781 | 0.80 | THRB (0.46) | THRBCA9CA12CA1CA2 | |
| SCHEMBL10415719 | 0.80 | CA1 (0.48) | THRBCA9CA12CA1CA2 | |
| SCHEMBL22904424 | 0.80 | CA1 (0.48) | THRBCA9CA12CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4735438-A2 | HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF KRAS | Merck Patent GmbH (DE) | 2026-05-06 | — | — | EP | disclosed |
| EP-4735452-A2 | HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF KRAS PROTEIN | Merck Patent GmbH (DE) | 2026-05-06 | — | — | EP | disclosed |
| US-12552791-B2 | Heterocyclic GLP-1 agonists | GASHERBRUM BIO, INC. (US) | 2026-02-17 | — | — | US | disclosed |
| US-12473283-B2 | Compounds and their use | DEBIOPHARM INTERNATIONAL S.A. (CH) | 2025-11-18 | — | — | US | disclosed |
| US-20250214999-A1 | HETEROCYCLIC GLP-1 AGONISTS | SHOUTI INC. | 2025-07-03 | — | — | US | disclosed |
| US-20250152719-A1 | FUSED IMIDE DERIVATIVE | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2025-05-15 | — | — | US | disclosed |
| CN-119823111-A | Condensed imide derivative | 正大天晴药业集团股份有限公司 | 2025-04-15 | — | — | CN | disclosed |
| WO-2025006753-A2 | HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF KRAS PROTEIN | MERCK PATENT GMBH (DE) | 2025-01-02 | — | — | WO | disclosed |
| WO-2025006783-A2 | HETEROBIFUNCTIONAL COMPOUNDS FOR THE DEGRADATION OF KRAS | MERCK PATENT GMBH (DE) | 2025-01-02 | — | — | WO | disclosed |
| EP-4434992-A1 | FUSED IMIDE DERIVATIVE | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2024-09-25 | — | — | EP | disclosed |
| CN-115151541-B | Novel compounds and uses thereof | 德彪药业国际股份公司 | 2024-06-25 | — | — | CN | disclosed |
| EP-4143183-A1 | HETEROCYCLIC GLP-1 AGONISTS | Gasherbrum Bio, Inc. (US) | 2023-03-08 | — | — | EP | disclosed |
| CN-115667250-A | Heterocyclic GLP-1 agonists | 加舒布鲁姆生物公司 | 2023-01-31 | — | — | CN | disclosed |
| CN-115151541-A | Novel compound and use thereof | 德彪药业国际股份公司 | 2022-10-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12552791-B2 | Heterocyclic GLP-1 agonists | GLP1R, NPY1R, NPY2R | THRB 158/4885CA9 855/4885CA12 1151/4885 |
| US-20250214999-A1 | HETEROCYCLIC GLP-1 AGONISTS | GLP1R, GIPR, GCGR | THRB 466/4885CA9 3044/4885CA12 4310/4885 |
| US-12473283-B2 | Compounds and their use | LSS, PGLS, LDHB | THRB 2353/4885CA9 819/4885CA12 1095/4885 |
| US-20250152719-A1 | FUSED IMIDE DERIVATIVE | WEE1, WEE2, CYP4F11 | THRB 3075/4885CA9 1073/4885CA12 1911/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.